Navigation Links
Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
Date:5/21/2012

JERUSALEM, Israel, May 21, 2012 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB), a developer of oral delivery systems, announced today that it was chosen to present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference taking place in Israel on May 21-23, 2012. The presentation will be given by Nadav Kidron, Oramed's President and CEO, on Wednesday, May 23rd, at 12:10 p.m. (IDT) during the BioPharma Session.

Event: 11th National Life Science & Technology Week ILSI-BIOMED Conference

Location: David InterContinental Hotel, Tel-Aviv, Israel. 

Date: Wednesday, May 23, 2012

Time: 12:10 p.m. (IDT), or 5:10 a.m. (EST) 

For more information on the upcoming ILSI Biomed conference, please visit their website:  http://www2.kenes.com/biomed/pages/home.aspx

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials, and with its GLP-1 analog capsule, currently entering Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.  

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com

Safe Harbor forForward-looking statements: Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Included therein are the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward-looking statements. The company undertakes no obligation to update or revise any forward-looking statements. 

Company and Investor Relations Contact:
Oramed Pharmaceuticals
Aviva Sherman
USA:   +1-646-240-4193
Int'l: +972-2-566-0001
       +972-54-792-4438
E-mail: aviva@oramed.com



'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals Granted Australian Patent for Important Part of the Companys Core Technology in Oral Delivery of Proteins
2. Oramed Pharmaceuticals Files US Patent Application for Combination Oral Treatment of Diabetes
3. Oramed Pharmaceuticals Announces Successful Phase 1 Clinical Trial Results for EnteraBio
4. Oramed Pharmaceuticals Chosen to Present at the 8th Annual Israel Strategic Partner and Venture Conference on September 22, 2011
5. Oramed Pharmaceuticals to Present at Rodman & Renshaw 13th Annual Global Investment Conference
6. Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule
7. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
8. Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association
9. Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.
10. Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.
11. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Va. , Feb. 12, 2016   National ... Hoey , RPh, MBA issued the following statement today ... released by the Centers for Medicare & ... raised by NCPA, beneficiary advocates and others: ... raised. We are still reviewing the full CMS analysis. ...
(Date:2/12/2016)...  This month,s issue of the Journal of ... in-depth look at various causes and consequences associated with rising health ... which has generated significant public outrage and calls for ... E. Happe , PharmD, MPH. --> JMCP ... --> In 2014 prescription drug spending in ...
(Date:2/12/2016)... PAULO , Feb. 12, 2016 ... commenced a cash tender offer (the "Tender Offer") ... million outstanding aggregate principal amount of its 6.500% ... and ISIN Nos. US44915JAA88/ USP5246AAF05) (the "Notes"). In ... soliciting (the "Consent Solicitation") consents (the "Consents") of ...
Breaking Medicine Technology:
(Date:2/12/2016)... Washington, DC (PRWEB) , ... ... ... the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to ... settings. The partnership will recruit top students from U.S. universities who will ...
(Date:2/12/2016)... Boca Raton, FL (PRWEB) , ... February 12, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – hosted over 250 members of South Florida’s philanthropic community at ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , ... , As Winston Churchill said, “Those who don’t learn from history are doomed to ... expect when they come knocking this year. But that takes time. , Take a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose Combination ... 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose combination ... garnering increased attention from all stakeholders in the development of new chemical entities. ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Each year, ... will be held in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical ... see new therapy products in action, learn more about their chosen field and network ...
Breaking Medicine News(10 mins):